Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;13(3):395-406.
doi: 10.2174/1570159x13999150424113345.

Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective

Affiliations
Review

Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective

Lurdes Tse et al. Curr Neuropharmacol. 2015.

Abstract

Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening side-effect that can occur in response to treatment with antipsychotic drugs. Symptoms commonly include hyperpyrexia, muscle rigidity, autonomic dysfunction and altered mental status. In the current review we provide an overview on past and current developments in understanding the causes and treatment of NMS. Studies on the epidemiological incidence of NMS are evaluated, and we provide new data from the Canada Vigilance Adverse Reaction Online database to elaborate on drug-specific and antipsychotic drug polypharmacy instances of NMS reported between 1965 and 2012. Established risk factors are summarized with an emphasis on pharmacological and environmental causes. Leading theories about the etiopathology of NMS are discussed, including the potential contribution of the impact of dopamine receptor blockade and musculoskeletal fiber toxicity. A clinical perspective is provided whereby the clinical presentation and phenomenology of NMS is detailed, while the diagnosis of NMS and its differential is expounded. Current therapeutic strategies are outlined and the role for both pharmacological and non-pharmacological treatment strategies in alleviating the symptoms of NMS are discussed.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Number of cases of NMS associated with atypical antipsychotics reported in the Canada Vigilance Adverse Reaction Online Database.
Fig. (2)
Fig. (2)
Number of cases of NMS associated with typical antipsychotics reported in the Canada Vigilance Adverse Reaction Online Database.
Fig. (3)
Fig. (3)
Etiopathogenesis of Neuroleptic Malignant Syndrome and its clinical manifestations. Khaki-coloured boxes describe risk factors associated with NMS, green ovals describe etiopathogenic mechanisms that lead to pathophysiological changes in orange polygons that result in clinical symptomatology in red stars. Abbreviations: ANS, autonomic nervous system; BP, blood pressure; Dp, dopamine; HR, heart rate; RR, respiration rate.

Similar articles

Cited by

References

    1. Delay J., Pichot P., Lemperiere T., Elissalde B., Peigne F. non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann. Med. Psychol. (Paris) 1960;118(1):145–152. - PubMed
    1. Neppe V.M. The neuroleptic malignant syndrome. A priority system. S. Afr. Med. J. 1984;65(13):523–525. - PubMed
    1. Gurrera R.J., Simpson J.C., Tsuang M.T. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr. Psychiatry. 2007;48(2):205–211. doi: 10.1016/j.comppsych.2006.10.004. - DOI - PubMed
    1. Pope H.G., Jr, Keck P.E., Jr, McElroy S.L. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am. J. Psychiatry. 1986;143(10):1227–1233. doi: 10.1176/ajp.143.10.1227. - DOI - PubMed
    1. American. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.

Substances

LinkOut - more resources